Amphastar Pharma (AMPH) Tops Q4 EPS by 12c, Slight Miss on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Amphastar Pharmaceuticals (AMPH) PT Raised to $24 at Needham & Company
March 13, 2018 6:31 AM EDTNeedham & Company raised its price target on Amphastar Pharmaceuticals (NASDAQ: AMPH) to $24.00 (from $23.00) while maintaining a Buy rating following Q4 results.
Analyst Serge Belanger commented, "AMPH reported a 4Q17 financials that mostly met or exceeded Street Consensus. Since AMPH saw minimal benefits... More
